Role of relaxin-2 in human primary osteosarcoma

Cancer Cell International

Volumn 13, Issue 1, 2013, Pages

  Ma, Jinfeng ^a   Niu, Min ^a   Yang, Wenjiu ^a   Zang, Lina ^a   Xi, Yongming ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Angiogenesis; Gene treatment; Metastases; Osteosarcoma; Prognosis; Relaxin 2

Indexed keywords

MESSENGER RNA; MONOCLONAL ANTIBODY; SERELAXIN; SMALL INTERFERING RNA;

ADULT; ADVANCED CANCER; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CANCER INHIBITION; CANCER STAGING; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION;

EID: 84878690525     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-13-59     Document Type: Article

References (26)

1. Broadhead ML, Clark JC, Myers DE, Dass CR, Choong PF. The molecular pathogenesis of osteosarcoma: a review. Sarcoma 2011, 2011:959248-959252. 3087974, 21559216.
2. Jaffe N. Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res 2009, 152:239-262. 10.1007/978-1-4419-0284-9_12, 20213394.
3. Chou AJ, Geller DS, Gorlick R. Therapy for osteosarcoma: where do we go from here?. Paediatr Drugs 2008, 10:315-327. 10.2165/00148581-200810050-00005, 18754698.
4. Trent JC. Rapid evolution of the biology and treatment of sarcoma. Curr Opin Oncol 2008, 20:393-394. 10.1097/CCO.0b013e328303ba31, 18525333.
5. Siegel HJ, Pressey JG. Current concepts on the surgical and medical management of osteosarcoma. Expert Rev Anticancer Ther 2008, 8:1257-1269. 10.1586/14737140.8.8.1257, 18699764.
6. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 2006, 6:1075-1085. 10.1586/14737140.6.7.1075, 16831079.
7. Sherwood OD. Relaxin's physiological roles and other diverse actions. Endocr Rev 2004, 25:205-234. 10.1210/er.2003-0013, 15082520.
8. Bathgate RA, Ivell R. SanbornBM, et al. International Union of Pharmacology LVII: recommendations for the nomenclature of receptors for relaxin family peptides. Pharmacol Rev 2006, 58:7-31. 10.1124/pr.58.1.9, 16507880.
9. Feng S, Agoulnik IU, Bogatcheva NV, Kamat AA, Kwabi-Addo B, Li R, Ayala G, Ittmann MM, Agoulnik AI. Relaxin promotes prostate cancer progression. Clinical Cancer Res 2007, 13:1695-1702.
10. Shabanpoor F, Separovic F, Wade JD. The human insulin superfamily of polypeptide hormones. Vitam Horm 2009, 80:1-31.
11. Johnson MR, Abdalla H, Allman AC, Wren ME, Kirkland A, Lighman SL. Relaxin levels in ovum donation pregnancies. Fertil Steril 1991, 56:59-61.
12. Brener SHL, Schoenfeld C, Amelar RD, Dubin L, Weiss G. Stimulation of human sperm cervical mucus penetration in vitro by relaxin. Fertil Steril 1984, 42:92-96.
13. Conrad KP, Novak J. Emerging role of relaxin in renal and cardiovascular function. Am J Physiol Regul Integr Comp Physiol 2004, 287:250-261.
14. Silvertown JD, Symes JC, Neschadim A, Nonaka T, Kao JCH, Summerlee AJ, Medin JA. Analog of H2 relaxin exhibits antagonistic properties and impairs prostate tumor growth. FASEB J 2007, 21:754-765. 10.1096/fj.06-6847com, 17197386.
15. Silvertown JD, Ng J, Sato T, Summerlee AJ, Medin JA. H2 relaxin overexpression increases in vivo prostate xenograft tumor growth and angiogenesis. Int J Cancer 2006, 118:62-73. 10.1002/ijc.21288, 16049981.
16. Silvertown JD, Geddes BJ, Summerlee AJ. Adenovirusmediated expression of human prorelaxin promotes the invasive potential of canine mammary cancer cells. Endocrinology 2003, 144:3683-3691. 10.1210/en.2003-0248, 12865351.
17. Binder C, Simon A, Binder L. Elevated concentrations of serum relaxinare associated with metastatic disease in breast cancer patients. Breast Cancer Res Treat 2004, 87:157-166. 10.1023/B:BREA.0000041622.30169.16, 15377840.
18. Einspanier A. Relaxin enhances in-vitro invasiveness of breast cancer cell lines by up-regulation of matrix metalloproteases. Mol HumReprod 2002, 8:789-796.
19. Kamat AA, Feng S, Agoulnik IU. The role of relaxin in endometrial cancer. Cancer Biol Ther 2006, 5:71-77. 10.4161/cbt.5.1.2289, 16322684.
20. Hombach-Klonisch S, Bialek J, Trojanowicz B. Relaxin enhances the oncogenic potential of human thyroid carcinoma cells. Am J Pathol 2006, 169:617-632. 10.2353/ajpath.2006.050876, 1698779, 16877360.
21. Facciolli A, Ferlin A, Gianesello L, Pepe A, Foresta C. Role of relaxin in human osteoclastogenesis. Ann N Y Acad Sci 2009, 1160:221-225. 10.1111/j.1749-6632.2008.03788.x, 19416193.
22. Ferlin A, Pepe A, Facciolli A, Gianesello L, Foresta C. Relaxin stimulates osteoclast differentiation and activation. Bone 2010, 46:504-513. 10.1016/j.bone.2009.10.007, 19833242.
23. Vinall RL, Tepper CG, Shi XB. The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7. Oncogene 2006, 25:2082-2093. 10.1038/sj.onc.1209246, 16434975.
24. Thompson VC, Morris TG, Cochrane DR. Relaxin becomes upregulated during prostate cancer progression to androgen independence and is negatively regulated by androgens. Prostate 2006, 66:1698-1709. 10.1002/pros.20423, 16998820.
25. Goldsmith LT, Weiss G, Palejwala S. Relaxin regulation of endometrial structure and function in the rhesus monkey. Proc Natl Acad Sci USA 2004, 101:4685-4689. 10.1073/pnas.0400776101, 384807, 15070778.
26. Palejwala S, Tseng L, Wojtczuk A, Weiss G, Goldsmith LT. Relaxin gene and protein expression and its regulation of procollagenase and vascular endothelial growth factor in human endometrial cells. Biol Reprod 2002, 66:1743-1748. 10.1095/biolreprod66.6.1743, 12021056.